Navigation Links
3SBio Announces Changes to its Board of Directors
Date:3/10/2010

SHENYANG, China, March 10 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced changes to its board of directors (the "Board"). Ms. Liping Xu, Executive Director and Vice President, will retire from the Board and her position as a company officer for health reasons, effective March 10, 2010. Ms. Xu was one of the founders of the company and has been a director of 3SBio and its predecessor company, Shenyang Sunshine, since 1993. Concurrently, effective March 10, 2010, Mr. Peiguo Cong will join the Board and serve as an independent, non-executive director.

Mr. Dan Lou, Chairman of the Board, said, "On behalf of the Board, I would like to thank Ms. Xu for her significant contributions as a founder, director and key executive of the company. We wish her well with her future endeavors." He continued, "We are also pleased to welcome Mr. Cong to the Board as an independent, non-executive director and look forward to his advice and counsel."

Mr. Peiguo Cong has been the managing partner of Beijing Jun You Law Firm since 1994. Mr. Cong also currently serves as a member of the Financial Securities Committee of the China National Lawyers Association, member of the All China Federation of Industry and Commerce, director of the Chinese Society of Mergers and Acquisitions, independent committee member of the Credit Committee of the National Development Bank, and part-time professor at Peking University. In addition, Mr. Cong serves as an independent director of China Southern Fund Management Company and Tianjin Lishen Battery Joint-Stock Co., Ltd. Mr. Cong obtained his bachelor's degree in law and master's degree in economic law from Peking University.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the ability of the company to avoid disruption to its business caused by changes to the Board and management; the ability of the company to recruit and retain suitable members of the Board and management; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update this forward-looking information, except as required under applicable law.

    For more information, please contact:

    Investor Contacts

    3SBio Inc.
     Bo Tan
     Chief Financial Officer
     Tel:   +86-24-2581-1820
     Email: ir@3SBio.com

     Tom Folinsbee
     Director of Investor Relations
     Tel:   +852-8191-6991
     Email: ir@3SBio.com

SOURCE 3SBio Inc.

Back to top

RELATED LINKS
http://www.3sbio.com

'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
2. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
3. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
4. 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia
5. 3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010
6. 3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM)
7. 3SBio Inc. Announces Unaudited Third Quarter 2009 Results
8. 3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
9. 3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
10. 3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
11. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017   Invitae Corporation (NYSE: NVTA), ... announced that members of the company,s management team will ... Care Conference on Monday, March 6, 2017 at approximately ... Boston, Massachusetts . The ... by visiting the investors section of the company,s website ...
(Date:2/20/2017)... 2017 This report analyzes the worldwide markets for ... Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Read the full ... are provided for the period 2015 through 2022. Also, a ...
(Date:2/20/2017)... ... February 20, 2017 , ... PuraCath Medical, an emerging ... dialysis, announced today that it has published the result of its recent research ... International (PDI), the official Journal of the International Society for Peritoneal Dialysis ...
(Date:2/18/2017)... February 18, 2017 Kurzlehrgang ... bei adoptiven Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms ... ... bekanntgab, wird Dr. Yoav Peretz , Scientific Director ... Entwicklung von Assays zum Nachweis intrazellulärer Zytokine bei adoptiven ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
Breaking Biology News(10 mins):